location_country:
Malaysia
Belgium
Australia
Russian Federation
Taiwan
Ukraine
France
Poland
Argentina
Canada
Korea, Republic of
South Africa
Sweden
Netherlands
Bulgaria
Hungary
Puerto Rico
China
Portugal
Germany
United States
United Kingdom
Italy
Brazil
Mexico
Czechia
Israel
Spain
Turkey

acronym: MAGNITUDE

location_facility: First Affiliated Hospital, Xi'an Jiaotong University

location_facility: Pomorski Uniwersytet Medyczny w Szczecinie

location_facility: University Health Network (UHN) Princess Margaret Cancer Centre

location_facility: Szpital Uniwersytecki NR 1 IM. Dr. Antoniego Jurasza

location_facility: Regional Clinical Center of Urology and Nephrology n.a. V.I. Shapoval

location_facility: Instituto COI de Pesquisa, Educacao e Gestao

location_facility: Adult Pediatric Urology & Urogynecology, P.C

location_facility: Clinical Diagnostic Centre of Nizhny Novgorod Region

location_facility: British Columbia Cancer Agency (BCCA) - Vancouver Centre

location_facility: Grand Hôpital de Charleroi, site Notre Dame

location_facility: Centro de Tratamento de câncer Medradius

location_facility: University of Texas MD Anderson Cancer Center

location_facility: Istanbul University Cerrahpasa Medical Faculty

location_facility: Cancer Hospital Chinese Academy of Medical Sciences

location_facility: Communal Noncommercial Enterprise of Lviv Regional Council 'Lviv Regional Clinical Hospital'

location_facility: Royal Cornwall Hospitals NHS Trust - Royal Cornwall Hospital

location_facility: Institut de Cancérologie de l'Ouest (ICO)

location_facility: Országos Onkológiai Intézet, C Belgyógyászati-Onkológiai és Klinikai Farmakológiai Osztály

location_facility: Urologica Praktyka Lekarska Adam Marcheluk

location_facility: Mayo Clinic - Division Of Hematology/oncology

location_facility: Urological Associates of Southern Arizona, P.C.

location_facility: Russian Scientific Center of Roentgenoradiology

location_facility: Southern Alberta Institute of Urology / Prostate Cancer Centre

location_facility: Hôpitaux Universitaires de Strasbourg - Hôpital de Hautepierre

location_facility: Sun Yat-Sen Memorial Hospital Sun Yat-sen University

location_facility: State Institution Institute of Urology NAMS of Ukraine based on Kyiv City Clinical Oncology Center

location_facility: Communal Nonprofit Enterprise 'Cherkasy Regional Oncology Dispensary Of Cherkasy Regional Council'

location_facility: Cemaic - Centro Privado de Especialidades Medicas Ambulatorias e Investigacion Clinica

location_facility: Instituto de Ensino E Pesquisa Sao Lucas

location_facility: Private Medical Institution Euromedservice

location_facility: Severance Hospital, Yonsei University Health System

location_facility: Ospedale S. Maria Della Misericordia Centro Operativo Studi Clinici SC Oncologia Medica

location_facility: Irmandade Santa Casa de Misericordia de Porto Alegre

location_facility: Beijing Cancer Hospital of Peking University

location_facility: Bekes Megyei Kozponti Korhaz Pandy Kalman Tagkorhaz

location_facility: Instituto de Investigaciones Clinicas Mar del Plata

location_facility: Fakultni nemocnice Plzen, Urologicka klinika

location_facility: MC Haaglanden Lok Antoniushove - Afd.Interne - INT

location_facility: ICESP - INSTITUTO DO CANCER DO ESTADO DE SAO PAULO OCTAVIO FRIAS de OLIVEIRA

location_facility: ME 'Poltava Regional Clinical Hospital n.a. M.V. Sklifosovsky of the Poltava Regional Council'

location_facility: Instituto Joinvilense De Hematologia e Oncologia

location_facility: Tongji Hospital, Tongji Medical College of Huazhong University of Science and Technology

location_facility: Goztepe Prof. Dr. Suleyman Yalcin Sehir Hastanesi

location_facility: Hospital Do Cancer De Barretos - Fundacao Pio Xii

location_facility: Ce 'Dnipropetrovsk Regional Clinical Hospital N.A. Mechnikov' of Dnipropetrovsk Rc

location_facility: Institut Regional du Cancer de Montpellier Val d'Aurelle

location_facility: Centre Hospitalier Universitaire de Liege Domaine Universitaire du Sart Tilman

location_facility: Istituto Oncologico Veneto Iov Irccs Padova

location_facility: Azienda Ospedaliero Universitaria Pisana

location_facility: The First Affiliated Hospital of Soochow University

location_facility: Cancer Centre of Southeastern Ontario (Kingston Regional Cancer Centre)

location_facility: Mexico Centre for Clinical Research, S.A. de C.V.

location_facility: Municipal Oncology Centre of Uzhgorod Central Municipal Clinical Hospitlal

location_facility: Kansas City Veterans Affairs Medical Center

location_facility: Consultorio de Especialidad en Urologia Privado

location_facility: Russian Scientific Center of Radiology and Surgical Technologies

location_facility: Instituto Portugues de Oncologia de Coimbra Francisco Gentil, EPE

location_facility: State Institution National Cancer Institute

location_facility: Szabolcs-Szatmar-Bereg Megyei Korhazak es Egyetemi Oktatokorhaz, Josa Andras Oktatokorhaz

location_facility: Guangzhou First Municipal People's Hospital

location_facility: Dr.Abdurrahman Yurtaslan Oncology Training and Research Hospital

location_facility: The Catholic University of Korea, Seoul St. Mary's Hospital

location_facility: Seoul National University Bundang Hospital

location_facility: ASST Grande Ospedale Metropolitano Niguarda

location_facility: Fort Wayne Medical Oncology and Hematology

location_facility: Tianjin Medical University Cancer Hospital

location_facility: Cukurova University, Faculty of Medicine

location_facility: Hospital Privado - Centro Medico de Cordoba

location_facility: Drug clinical trial ethics committee of Ningbo First Hospital

location_facility: Thomayerova nemocnice, Onkologicka klinika

location_facility: Instituto D'Or de Pesquisa e Ensino (IDOR)

location_facility: Centro Hospitalar Lisboa Norte, EPE/Hosp. Santa Maria

location_facility: A.O.U. Città della Salute e della Scienza

location_facility: Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - Panstwowy Instytut Badawczy

location_facility: Instituto de Assistência Médica ao Servidor Público Estadual - HSPE-FMO

location_facility: Municipal Institution 'Clinical Oncology Dispensary' Under Dnipropetrovsk Regional Council

location_facility: IOS - Instituto de Oncologia de Sorocaba Dr. Gilson Delgado

location_facility: Southwest Hospital, The Third Military Medical University

location_facility: Municipal non-profit enterprise 'Regional Center of Oncology'

location_facility: Kyungpook National University Chilgok Hospital

location_facility: Wojewodzki Szpital Specjalistyczny im. M. Kopernika w Lodzi

location_facility: British Columbia Cancer Agency - Vancouver Island Centre

location_facility: Oncologia Medica - Azienda Ospedaliero Universitaria Di Parma

location_facility: Centrum Onkologii im. Prof. F. Lukaszczyka

location_facility: Icahn School of Medicine at Mount Sinai - The Derald H. Ruttenberg

location_facility: PERSONAL - Oncologia de Precisão e Personalizada

location_facility: Specialized Hospital for Active Treatment in Oncology EAD

location_facility: Ivano-Frankivsk Regional Clinical Hospital

location_facility: Renji Hospital, Shanghai Jiaotong University School of Medicine

location_facility: H. Santo António - Centro Hospitalar do Porto

location_facility: Dnipropetrovsk State Medical Academy, Dnipropetrovsk City Multifield Clinical Hospital # 4

location_facility: The Fifth People's Hospital of Shanghai, Fudan University

location_facility: Champalimaud Foundation Champalimaud Centre

location_facility: Oncologia Medica A - Ist Naz Tumori G Pascale

location_facility: Fondazione Policlinico Universitario A. Gemelli IRCCS

location_facility: Fujian Medical University Union Hospital

location_facility: CIONC - Centro Integrado de Oncologia de Curitiba

location_facility: Tambov Regional Oncology Clinical Dispansary

title: A Phase 3 Randomized, Placebo-controlled, Double-blind Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Subjects With Metastatic Prostate Cancer

summary: The purpose of this study is to evaluate the effectiveness of niraparib in combination with abiraterone acetate plus prednisone (AAP) compared to AAP and placebo.


title: A Multicenter, Double-Blind, Randomized Phase 3 Clinical Trial Evaluating the Efficacy and Safety of Sintilimab vs. Placebo, in Combination With Chemotherapy, for First-Line Treatment of Unresectable, Locally Advanced, Recurrent, or Metastatic Esophageal Squamous Cell Carcinoma (ORIENT-15)

summary:
This is a randomized, double-blind multi-center, phase III study comparing the efficacy and safety of sintilimab or placebo in combination with chemotherapy as first-line treatment in subjects with unresectable, locally advanced recurrent or metastatic esophageal squamous cell carcinoma.

After the interim analysis conducted by the iDMC, an open-label assignment of experimental arm therapy will continue in regions outside of China, in order to further evaluate the efficacy and safety of sintilimab in combination with chemotherapy in subjects representing the western population with advanced esophageal squamous cell carcinoma

study_start_date_type: Actual

status: Recruiting

study_completion_date_type: Anticipated

study_type: Interventional

design_allocation: Randomized

primary_purpose: Treatment

enrollment_type: Anticipated

ipd_sharing: No

lead_sponsor: Innovent Biologics (Suzhou) Co. Ltd.

location_country:
Spain
France
Hungary
Belgium
Australia
China
United States

location_facility: Hospital Universitari de Girona Doctor Josep Trueta

location_facility: University Hospital Marqués de Valdecilla

location_facility: Complexo Hospitalario Universitario de Santiago

location_facility: IACT Health - John B. Amos Cancer center

location_facility: Hospital Universitari Arnau de Vilanova de Lleida

location_facility: St. Joseph Heritage Healthcare - Virginia K. Crosson Cancer Center

location_facility: Consorci Hospital General Universitari de València

location_facility: Hospital Universitario Fundacion Jimenez Diaz

location_facility: Parc Taulí Sabadell Hospital Universitari

intervention_type: Drug

lead_sponsor_type: industriel

status_simplified: Ongoing


title: A Multicentre, Double-blind, Randomized, Placebo Controlled, Parallel Group, Phase 3, Safety Extension Study to Evaluate the Safety and Tolerability of Tezepelumab in Adults and Adolescents With Severe Uncontrolled Asthma (DESTINATION)

acronym: DESTINATION

summary: Subjects who completed either D5180C00007 or D5180C00009 will be offered the opportunity to consent for the Multicentre, Double-blind, Randomized, Placebo Controlled, Parallel Group, Phase 3, Safety Extension Study to Evaluate the Safety and Tolerability of Tezepelumab in Adults and Adolescents with Severe Uncontrolled Asthma. The study consists of a treatment phase, followed by a follow-up phase where subjects will not receive IP. The length of the follow up phase is determined by which study the subject had previously completed.

status: Active, not recruiting

enrollment_type: Actual

ReferenceType: derived

ReferenceCitation: Menzies-Gow A, Ponnarambil S, Downie J, Bowen K, Hellqvist Å, Colice G. DESTINATION: a phase 3, multicentre, randomized, double-blind, placebo-controlled, parallel-group trial to evaluate the long-term safety and tolerability of tezepelumab in adults and adolescents with severe, uncontrolled asthma. Respir Res. 2020 Oct 21;21(1):279. doi: 10.1186/s12931-020-01541-7.

family: Menzies-Gow

full_name: Andrew Menzies-Gow

given: Andrew

sequence: first

family: Ponnarambil

full_name: Sandhia Ponnarambil

given: Sandhia

sequence: additional

family: Downie

full_name: John Downie

given: John

family: Bowen

full_name: Karin Bowen

given: Karin

family: Hellqvist

full_name: Åsa Hellqvist

given: Åsa

family: Colice

full_name: Gene Colice

given: Gene

bso_classification: Medical research

currency_apc_doaj: GBP

datasource: user

genre: journal-article

genre_raw: journal-article

journal_name: Respiratory Research

oa_colors: green gold

oa_host_type: publisher;repository

evidence: oa journal (via doaj)

host_type: publisher

license: cc-by

license_normalized: cc-by

version: publishedVersion

evidence: oa repository (via pmcid lookup)

host_type: repository

license_normalized: no license

repository_normalized: PubMed Central

publisher: Springer Science and Business Media LLC

publisher_dissemination: Springer-Nature

publisher_group: Springer-Nature

publisher_normalized: Springer

lead_sponsor: AstraZeneca

location_country:
Austria
Brazil
South Africa
Saudi Arabia
Vietnam
Germany
France
Korea, Republic of
Poland
Israel
Argentina
Australia
Russian Federation
Turkey
United States
Canada
Taiwan
Ukraine

intervention_type: Other


title: A Phase 2/3 Randomized, Controlled, Open-Label Study of KRT 232 in Subjects With Primary Myelofibrosis (PMF), Post Polycythemia Vera MF (Post-PV-MF), Or Post Essential Thrombocythemia MF (Post-ET-MF) Who Are Relapsed or Refractory to Janus Kinase (JAK) Inhibitor Treatment

acronym: BOREAS

summary:
This study evaluates KRT-232, a novel oral small molecule inhibitor of MDM2, for the treatment of patients with myelofibrosis (MF) who no longer benefit from treatment with a JAK inhibitor. Inhibition of MDM2 is a novel mechanism of action in MF.

This study will be conducted in 2 phases. Phase 2 will determine the KRT-232 recommended dose and dosing schedule; Phase 3 will test KRT-232 vs Best Available Therapy (BAT). Patients in the Phase 3 part of the study will be randomized 2:1 to receive either KRT-232 (Arm 1) or BAT (Arm 2). The BAT administered will be determined by the treating physician, with the option to "cross-over" to KRT-232 treatment after 6 months of BAT or if the disease worsens at any time.

ReferenceType: background

ReferenceCitation: Al-Ali, H.K.; Delgado, R.G.; Lange, A.; Pluta, A.; McLornan, D.; Vachhani, P.; Damaj, G.L.; Jost, P.J.; Rejto, L.; Hus, M.; et al. KRT-232, A First-In-Class, Murine Double Minute 2 Inhibitor, for Myelofibrosis Relapsed or Refractory to Janus-Associated Kinase Inhibitor Treatment. Eha. Libr. 2020, 295035, S215

lead_sponsor: Kartos Therapeutics, Inc.

location_country:
Italy
United States
Germany
France
Czechia
Bulgaria
Poland
Hungary
Australia
Spain
Canada
United Kingdom

location_facility: Hospital Universitario de Gran Canaria Doctor Negrin

location_facility: University Multiprofile Hospital for Active Treatment Dr. Georgi Stranski, Pleven

location_facility: Hospital Universitario Virgen de la Victoria

location_facility: Centre Hospitalier Universitaire de Poitiers

location_facility: Hospital Universitario Puerta de Hierro - Majadahonda

location_facility: Dél-pesti Centrumkórház - Országos Hematológiai és Infektológiai Intézet

location_facility: Complejo Hospitalario de Navarra - H. de Navarra, Hematología C/ de Irunlarrea, 3, Pamplona

location_facility: Center Hospitalier Universitaire d'Angers

location_facility: University Multiprofile Hospital for Active Treatment Saint Ivan Rilski, Sofia

location_facility: Guy's and Saint Thomas' NHS Foundation Trust

location_facility: UKE - Universitätsklinikum Hamburg-Eppendorf

location_facility: Centre Hospitalier Regional Universitaire Brest Hopital Morvan

location_facility: Samodzielny Publiczny Szpital Kliniczny nr 1 w Lublinie

location_facility: Samodzielny Publiczny Zakład Opieki Zdrowotnej Zespół Szpitali Miejskich

location_facility: University Multiprofile Hospital for Active Treatment Alexandrovska, Sofia

location_facility: University of Southern California Norris Comprehensive Cancer Center

location_facility: Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" - IRST IRCCS

location_facility: Washington University School of Medicine

location_facility: Dolnośląskie Centrum Transplantacji Komórkowych z Krajowym Bankiem Dawców Szpiku

location_facility: Centre Hospitalier Universitaire of Caen Normandie - Côte de Nacre

location_facility: SPZOZ MSWiA z Warminsko - Mazurskim Centrum Onkologii

location_facility: Clinical Research Center Spółka z Ograniczoną Odpowiedzialnością Medic-R sp. k.

location_facility: Northwestern University Feinberg School of Medicine

location_facility: Debreceni Egyetem Orvos es Egeszsegtudomanyi Centrum

location_facility: Institut Universitaire du Cancer de Toulouse Oncopole

location_facility: Policlinico Universitario Agostino Gemelli

location_facility: University Multiprofile Hospital for Active Treatment Sveti Georgi, Plovdiv

location_facility: The University of Texas MD Anderson Cancer Center

location_facility: Specialized Hospital for Active Therapy of Hematological Disorders

location_facility: Hospital Universitari Germans Trias i Pujol

location_facility: Universitätsmedizin der Johannes Gutenberg Universität Mainz

location_facility: Wojewodzki Szpital Specjalistyczny im. Janusza Korczaka w Slupsku Sp. z o.o.

location_facility: Hopital Paul Brousse - Aphp Hôpitaux Universitaires Paris Su

location_facility: Klinikum Rechts der Isar der Technischen Universität München Apotheke

location_facility: Szabolcs-Szatmár-Bereg Megyei Kórházak és Egyetemi Oktatókórház

location_facility: Centre Hospitalier Universitaire D'Amiens (Hopital Sud) - Hématologie Clinique

location_facility: Centre Hospitalier Universitaire de Nîmes

location_facility: Gemeinschaftspraxis Haematologie - Onkologie - Hauptstelle

location_facility: The Ohio State University Comprehensive Cancer Center

location_facility: University Hospitals Birmingham NHS Foundation Trust

location_facility: Brookdale University Hospital and Medical Center

location_facility: Oxford University Hospitals NHS Foundation Trust

location_facility: Szpital Specjalistyczny w Brzozowie Podkarpacki Ośrodek Onkologiczny im. Ks. B. Markiewicza

location_facility: New York Presbyterian/Weill Cornell Medical Center

location_facility: Acibadem City Clinic Tokuda Hospital, Sofia


status: Terminated

lead_sponsor: Incyte Corporation

location_country:
Italy
United States
France
Spain
Germany
United Kingdom

location_facility: Universitatsklinikum Jena, Klinik fur Kinder und Jugendmedizin

location_facility: University Hospitals Cleveland Medical Center - Rainbow Babies and Children's Hospital

location_facility: Hospital Clinico de Santiago de Compostela

location_facility: Children's Hospital of Philadelphia - Center for Childhood Cancer Research

location_facility: Centre Hospitalier Universitaire de Rennes

location_facility: Hospital Universitari i Politecnic La Fe

location_facility: Children's Hospital Colorado - Center for Cancer and Blood Disorders

location_facility: Azienda Ospedaliero Unversitatia Policlinico - Vittorio Emanuele - Presido Ospedaliero G. Rodolico

location_facility: Central Manchester University Hospital - Royal Manchester Children's Hospital

location_facility: Doernbecher Children's Hospital - Division of Pediatric Hematology

location_facility: Nemours/A.I. duPont Hospital for Children

location_facility: Great Ormond Street Hospital for Children

location_facility: AOU Citta della Salute e della Scienza di Torino - Ospedale Regina Margherita

study_completion_date_type: Actual

source: euctr

title: An Open-Label, Single-Arm, Phase 1/2 Study Evaluating the Safety and Efficacy of Itacitinib in Combination With Corticosteroids for the Treatment of Steroid-Naive Acute Graft-Versus-Host Disease in Pediatric Subjects

summary: The purpose of this study is to evaluate itacitinib in combination with corticosteroids for the treatment of Grades II to IV acute graft-versus-host disease (aGVHD) in steroid-naive pediatric participants.

status_simplified: Unknown


title: A Phase 3, Matrix Design, Partially Double-Blind, Randomized Study of the Efficacy and Safety of 50 mg Lonafarnib/100 mg Ritonavir BID With and Without 180 mcg PEG IFN-alfa-2a for 48 Weeks Compared With PEG IFN-alfa-2a Monotherapy and Placebo Treatment in Patients Chronically Infected With Hepatitis Delta Virus Being Maintained on Anti-HBV Nucleos(t)Ide Therapy (D-LIVR)

acronym: D-LIVR

summary: Two LNF-containing regimens will be evaluated in the D-LIVR Phase 3 study: (1) LNF/RTV/PEG IFN-alfa-2a and (2) LNF/RTV. Each of these arms will have efficacy endpoints that measure clinical benefit with regard to viral suppression and alanine aminotransferase (ALT) normalization. For each LNF-containing regimen, a composite endpoint of EOT (48 weeks) virologic response and ALT normalization will be used. Virologic response will be defined as a 2 log10 IU/mL reduction from baseline.

lead_sponsor: Eiger BioPharmaceuticals

location_country:
Greece
Romania
Belgium
Russian Federation
Taiwan
Ukraine
Pakistan
France
Moldova, Republic of
Canada
Sweden
Switzerland
Bulgaria
United States
Germany
United Kingdom
Italy
Mongolia
Israel
New Zealand
Spain
Turkey

location_facility: Spitalul Universitar de Urgenta Militar Central "Dr. Carol Davila"

location_facility: Office for treatment of patients with viral hepatitis GBU Sakha (Yakutia) "Yakut Republican clinical hospital"

location_facility: Azienda Ospedaliera Universitaria Policlinico G. Martino

location_facility: Kaiser Permanente Medical Center Sacramento

location_facility: Azienda Ospedaliero Universitaria di Parma

location_facility: Institutul National de Boli Infectioase "Prof. Dr. Matei Bals"

location_facility: IRCCS Ospedale Casa Sollievo della Sofferenza

location_facility: State Budgetary Educational Institution of Higher Profesional Education "Stavropol State Medical University" of MoH

location_facility: National medical research center Phthisiopulmonology and infectious diseases of the Ministry of health of the Russian Federation

location_facility: Azienda Ospedaliera Universitaria "Federico II"

location_facility: Azienda Ospedaliera Città della Salute e della Scienza di Torino

location_facility: McGill University Health Centre/Glen Site / Royal Victoria Hospital

location_facility: Azienda Ospedaliero Universitaria Pisana

location_facility: Hadassah University Hospital - Ein Kerem

location_facility: Clinic of the Ministry of health of the South Ural state medical UNIVERSITY Russia, 2 infectious diseases Department.

location_facility: Medical Center 'Ok!Clinic+' of International Institute of Clinical Research LLC

location_facility: Azienda Ospedaliera Universitaria Policlinico Tor Vergata

location_facility: ISMP Spitalul Clinic Republican "Timofei Mosneaga"

location_facility: Municipal non-profit enterprise " Vinnytsia city clinical hospital No. 1"

location_facility: Zentrum für Infektiologie Berlin Prenzlauer Berg GmbH

location_facility: University Hospital of Sumy State University

location_facility: Inselspital Bern, Hepatologie, Bauchzentrum, INO- A, Ms. Kathrin Husi

location_facility: Spitalul Clinic Judetean de Urgenta Cluj Napoca

location_facility: University of Miami Schiff Center for Liver Disease

location_facility: Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia (Presidio Spedali Civili)

location_facility: Kaohsiung Medical University Chung-Ho Memorial Hospital

location_facility: University of California Davis Health System

location_facility: Universita di Modena e Reggio Emilia. Nuovo Ospedale civil

location_facility: Krasnodar specialized clinical infectious diseases hospital

location_facility: Fondazione IRCCS CA' Granda Ospedale Maggiore Policlinico

location_facility: Medical Center "Nov Rehabilitatsionen Tsentar", EOOD

location_facility: Cliniques Universitaires de Bruxelles Hopital Erasme

location_facility: Azienda Socio Sanitaria Territoriale Niguarda (Grande Ospedale Metropolitano Niguarda)

location_facility: Azienda Ospedaliero Universitaria Ospedali Riuniti di Foggia

location_facility: Hospital of the state institution "National Institute of Therapy named after L.T. Maloi of the National Academy of Medical Sciences of Ukraine"

location_facility: Municipal Enterprise "Poltava Regional Clinical Infectious Hospital of Poltava Regional Council"

location_facility: University of Texas Southwestern Medical Center

location_facility: Acibadem City Clinic Tokuda Hospital Ead


ipd_sharing_description:
Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.

This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com

lead_sponsor: Novartis Pharmaceuticals

location_country:
Greece
Australia
Belgium
Russian Federation
Taiwan
India
France
Japan
Poland
Slovakia
Argentina
Canada
Korea, Republic of
Sweden
Switzerland
Philippines
Bulgaria
Hungary
Portugal
Germany
United States
United Kingdom
Italy
Austria
Mexico
Czechia
Israel
Spain
Turkey

acronym: SUNSHINE

ipd_sharing: Undecided

type: EudraCT Number

title: A Randomized, Double-blind, Multi-center Study Assessing Short (16 Weeks) and Long-term Efficacy (up to 1 Year), Safety, and Tolerability of 2 Subcutaneous Secukinumab Dose Regimens in Adult Patients With Moderate to Severe Hidradenitis Suppurativa (SUNSHINE).

summary: The purpose of this study is to demonstrate superiority of secukinumab at Week 16, based on Hidradenitis Suppurativa Clinical Response (HiSCR) rates versus placebo, along with the maintenance of efficacy of secukinumab at Week 52 in subjects with moderate to severe HS. Moreover, this study will also assess the safety and tolerability of secukinumab.


lead_sponsor: Trizell Ltd

location_country:
Italy
United States
Germany
France
Poland
Australia
Russian Federation
Canada
United Kingdom

acronym: INFINITE

location_facility: Masonic Cancer Center - University of Minnesota

location_facility: Petrov National Medical Research Center of Oncology

location_facility: New York University (NYU) Clinical Cancer Center

location_facility: Azienda Ospedaliero Universitaria Senese, Cancer Immunotherapy

location_facility: Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori

location_facility: Centrum Onkologii Instytut im. Marii Sklodowskiej - Curie, Klinika Nowotworow Tkanek Miekkich, Kosci i Czerniakow

location_facility: Volgograd Regional Clinical Oncology Dispensary

location_facility: University of Pennsylvania Abramson Cancer Center

location_facility: Institut Universitaire de Cardiologie et de Pneumologie De Quebec

location_facility: Budget Healthcare Institution of Omsk region Clinical Oncology Dispensary

location_facility: Kursk Regional Clinical Oncology Dispensary

location_facility: State Budget Educational Institution of Higher Professional Education Pavlov First Saint Petersburg State Medical University of Ministry of Healthcare of Russian Federation

location_facility: University of California, San Francisco (UCSF)

location_facility: H. Lee Moffitt Cancer Center & Research Institute

location_facility: University of California, Los Angeles (UCLA) - Medical Center

title: A Phase 3, Open-Label, Randomized, Parallel Group Study to Evaluate the Efficacy and Safety of Intrapleural Administration of Adenovirus-Delivered Interferon Alpha-2b (rAd-IFN) in Combination With Celecoxib and Gemcitabine in Patients With Malignant Pleural Mesothelioma

summary:
This study will evaluate intrapleural administration of Adenovirus-Delivered Interferon Alpha-2b (rAd-IFN) in combination with Celecoxib and Gemcitabine in patients with histologically confirmed Malignant Pleural Mesothelioma (MPM) who have failed a minimum of 1 treatment regimen and a maximum of 2 treatment regimens, 1 of which must have been an anti-folate and platinum combination regimen.

Eligible patients will be randomized 1:1 to either:

Treatment group: rAd-IFN + Celecoxib followed by Gemcitabine
Control group: Celecoxib followed by Gemcitabine

Patients randomized to the treatment group will receive rAd-IFN administered into the pleural space via an Intrapleural catheter (IPC) or similar intrapleural device on study Day 1.

The primary objective of this study is to compare the overall survival (OS) associated with rAd IFN, when administered with celecoxib and gemcitabine, versus that associated with celecoxib and gemcitabine alone for the treatment of patients with MPM


location_country:
Italy
Brazil
Sweden
Switzerland
Netherlands
United Kingdom
Germany
France
Czechia
Japan
Korea, Republic of
Norway
Hungary
Belgium
Argentina
Australia
Spain
United States
Latvia
Canada

acronym: CIRRUS I

type: Other Identifier

title: A Partially-blinded, Active-controlled, Multicenter, Randomized Study Evaluating Efficacy, Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) of an Anti-CD40 Monoclonal Antibody, CFZ533, in de Novo and Maintenance Kidney Transplant Recipients (CIRRUS I)

summary:
The purpose of this study is to investigate the safety, efficacy, pharmacokinetics (PK) and pharmacodynamics (PD) of three CFZ533 dose regimens in kidney transplant recipients.

This study will allow assessment of the ability of CFZ533 to replace Calcineurin inhibitors (CNIs) in terms of anti-rejection efficacy, while providing better renal function with a better safety and tolerability profile. Results of this study will be used to inform the CFZ533 dose and regimen selection for investigation in later phases of clinical development.


lead_sponsor: Janssen Research & Development, LLC

location_country:
Brazil
Netherlands
Germany
France
Czechia
Japan
Israel
Poland
Spain
Turkey
United States
United Kingdom
Canada

location_facility: Instituto COI de Pesquisa, Educacao e Gestao

location_facility: Cancer & Hematology Centers of Western Michigan, PC

location_facility: Szpital Specjalistyczny w Brzozowie Podkarpacki Osrodek Onkologiczny im. Ks. B. Markiewicza

location_facility: Centrum Onkologii Ziemi Lubelskiej im. św. Jana z Dukli

location_facility: Szpital Kliniczny Przemienienia Panskiego Uniwersytetu Medycznego im. Karola Marcinkowskiego

location_facility: University of Texas, MD Anderson Cancer Center

location_facility: Fort Wayne Medical Oncology and Hematology, Inc.

location_facility: University of Pittsburgh Medical Center (UPMC) - Hillman Cancer Center

location_facility: Institut Universitaire du cancer de Toulouse-Oncopole

location_facility: IBCC Instituto Brasileiro de Controle do Cancer

location_facility: Instituto de Ensino E Pesquisa Sao Lucas

location_facility: Saint Luke's Hospital - Saint Luke's Cancer Specialists

location_facility: National Hospital Organization Shibukawa Medical Center

location_facility: National Hospital Organization Okayama Medical Center

location_facility: Ondokuz Mayis Universitesi Tip Fakultesi

location_facility: The Gordon & Leslie Diamond Health Care Center

location_facility: Dr.Abdurrahman Yurtaslan Oncology Training and Research Hospital

location_facility: Wojewodzki Szpital Specjalistyczny im. Janusza Korczaka

location_facility: Samodzielny Publiczny Zaklad Opieki Zdrowotnej Zespol Szpitali Miejskich

location_facility: Rambam Med.Center - Hematology Institute

location_facility: Klinikum Großhadern der Ludwig-Maximilians-Universität

location_facility: National Hospital Organization Matsumoto Medical Center

location_facility: Swietokrzyskie Centrum Onkologii SPZOZ w Kielcach

location_facility: National Hospital Organization Kumamoto Medical Center

location_facility: Albert Schweitzer ziekenhuis-lokatie Dordwijk

location_facility: Universitaetsklinikum Tuebingen der Eberhard-Karls-Universitaet, Abteilung fuer Innere Medizin II,

location_facility: Ankara University School of Medicine, Cebeci Hospital

location_facility: Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - Panstwowy Instytut Badawczy

location_facility: Centre Hospitalier Départmental La Roche sur Yon

location_facility: Kobe City Medical Center General Hospital

location_facility: phase 3 - Hämatoonkologischer Studienkreis am Klinikum Aschaffenburg

location_facility: Istanbul University Istanbul Medical Faculty

location_facility: University Hospital Kyoto Perfectural University of Medicine

location_facility: Fakultni nemocnice Plzen, Hemato-onkologicke oddeleni

title: A Phase 3 Study Comparing Daratumumab, VELCADE (Bortezomib), Lenalidomide, and Dexamethasone (D-VRd) With VELCADE, Lenalidomide, and Dexamethasone (VRd) in Subjects With Untreated Multiple Myeloma and for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy

summary: The purpose of this study to determine if the addition of daratumumab to bortezomib + lenalidomide + dexamethasone (VRd) will improve overall minimal residual disease (MRD) negativity rate compared with VRd alone.


title: A Multicenter, Randomized, Sham-controlled Study to Evaluate Safety and Efficacy After Treatment With the Nuvaira™ Lung Denervation System in Patients With Chronic Obstructive Pulmonary Disease (COPD)

summary: The purpose of this study is to confirm the safety and efficacy of the Nuvaira Lung Denervation System (Nuvaira System) in the treatment of COPD.

ReferenceCitation: Agrawal A. Interventional Pulmonology: Diagnostic and Therapeutic Advances in Bronchoscopy. Am J Ther. 2021 Feb 9;28(2):e204-e216. doi: 10.1097/MJT.0000000000001344. Review.

family: Agrawal

full_name: Abhinav Agrawal

given: Abhinav

journal_name: American Journal of Therapeutics

publisher: Ovid Technologies (Wolters Kluwer Health)

publisher_dissemination: Wolters Kluwer Health

publisher_group: Wolters Kluwer Health

publisher_normalized: Wolters Kluwer Health

ReferenceCitation: Slebos DJ, Degano B, Valipour A, Shah PL, Deslée G, Sciurba FC; AIRFLOW-3 Trial Study Group. Design for a multicenter, randomized, sham-controlled study to evaluate safety and efficacy after treatment with the Nuvaira® lung denervation system in subjects with chronic obstructive pulmonary disease (AIRFLOW-3). BMC Pulm Med. 2020 Feb 13;20(1):41. doi: 10.1186/s12890-020-1058-5.

family: Slebos

full_name: Dirk-Jan Slebos

given: Dirk-Jan

name: on behalf of the AIRFLOW-3 Trial Study Group

family: Degano

full_name: Bruno Degano

given: Bruno

family: Valipour

full_name: Arschang Valipour

given: Arschang

family: Shah

full_name: Pallav L. Shah

given: Pallav L.

family: Deslée

full_name: Gaetan Deslée

given: Gaetan

family: Sciurba

full_name: Frank C. Sciurba

given: Frank C.

journal_name: BMC Pulmonary Medicine

evidence: oa repository (via OAI-PMH doi match)

repository_institution: PubMed Central - Europe PMC

repository_institution: Le Centre pour la Communication Scientifique Directe - HAL - memSIC

repository_normalized: HAL

repository_institution: University of Groningen / Centre for Information Technology - University of Groningen research database

repositories:
HAL
PubMed Central
pure.rug.nl

ipd_sharing: Yes

ipd_sharing_description: Individual participant data that underlie the results reported in this article, after deidentification (text, tables, figures, and appendices).

lead_sponsor: Nuvaira, Inc.

location_country:
Austria
Netherlands
Germany
France
United States
United Kingdom

location_facility: University of Pittsburgh Medical Center (UPMC)

location_facility: University Medical Center Groningen (UMCG)

location_facility: Ohio State University Wexner Medical Center

location_facility: Medical University of South Carolina (MUSC)

location_facility: University of Alabama at Birmingham (UAB) Lung Health Center


ReferenceCitation: Grünewald S, Politz O, Bender S, Héroult M, Lustig K, Thuss U, Kneip C, Kopitz C, Zopf D, Collin MP, Boemer U, Ince S, Ellinghaus P, Mumberg D, Hess-Stumpp H, Ziegelbauer K. Rogaratinib: A potent and selective pan-FGFR inhibitor with broad antitumor activity in FGFR-overexpressing preclinical cancer models. Int J Cancer. 2019 Sep 1;145(5):1346-1357. doi: 10.1002/ijc.32224. Epub 2019 Mar 13.

family: Grünewald

full_name: Sylvia Grünewald

given: Sylvia

family: Politz

full_name: Oliver Politz

given: Oliver

family: Bender

full_name: Sebastian Bender

given: Sebastian

family: Héroult

full_name: Mélanie Héroult

given: Mélanie

family: Lustig

full_name: Klemens Lustig

given: Klemens

family: Thuss

full_name: Uwe Thuss

given: Uwe

family: Kneip

full_name: Christoph Kneip

given: Christoph

family: Kopitz

full_name: Charlotte Kopitz

given: Charlotte

family: Zopf

full_name: Dieter Zopf

given: Dieter

family: Collin

full_name: Marie‐Pierre Collin

given: Marie‐Pierre

family: Boemer

full_name: Ulf Boemer

given: Ulf

family: Ince

full_name: Stuart Ince

given: Stuart

family: Ellinghaus

full_name: Peter Ellinghaus

given: Peter

family: Mumberg

full_name: Dominik Mumberg

given: Dominik

family: Hess‐Stumpp

full_name: Holger Hess‐Stumpp

given: Holger

family: Ziegelbauer

full_name: Karl Ziegelbauer

given: Karl

journal_name: International Journal of Cancer

oa_colors: green hybrid

evidence: open (via crossref license)

license: cc-by-nc

license_normalized: cc-by-nc

publisher: Wiley

publisher_dissemination: Wiley

publisher_group: Wiley

publisher_normalized: Wiley

title: Rogaratinib: A potent and selective pan‐FGFR inhibitor with broad antitumor activity in FGFR‐overexpressing preclinical cancer models

status: Completed

lead_sponsor: Bayer

location_country:
Finland
Australia
Belgium
Russian Federation
Denmark
Taiwan
France
Japan
Poland
Slovakia
Canada
Korea, Republic of
Sweden
Hong Kong
Netherlands
Switzerland
Singapore
Hungary
Ireland
China
Portugal
United States
Germany
United Kingdom
Italy
Austria
Czechia
Israel
Spain

location_facility: IRST Istituto Scientifico Romagnolo per studio e cura tumori

location_facility: Centrum Onkologii im. Prof. Franciszka Lukaszczyka

location_facility: Centre de Lutte Contre le Cancer François Baclesse

location_facility: Clalit Health Services Rabin Medical Center-Beilinson Campus

location_facility: Huadong Hospital, Affiliated to Fudan University

location_facility: Moscow Scient. Res. Institute of Oncology n.a P.A. Hertzen

location_facility: Ciutat Sanitària i Universitaria de la Vall d'Hebron

location_facility: Szpital Kliniczny Przemienienia Panskiego

location_facility: NJ Drum Tower Hospital, the Affil Hos of NJ Univ Med School

location_facility: Fondazione IRCCS Istituto Nazionale dei Tumori

location_facility: IRCCS Istituto Europeo di Oncologia (IEO)

location_facility: FuJian Medical University Union Hospital

location_facility: Fifth Medical Center, General Hospital of the Chinese People

location_facility: Universitätsmedizin der Johannes Gutenberg Universität Mainz

location_facility: Saitama Medical University International Medical Center

location_facility: First Affiliated Hospital of Guangzhou Medical University

location_facility: Fondazione Policlinico Universitario Agostino Gemelli IRCCS

location_facility: Princess Margaret Hospital-University Health Network

location_facility: Samodzielny Publiczny Zespol Gruzlicy i Chorob Pluc

location_facility: Hadassah Hebrew University Hospital Ein Kerem

location_facility: Hospital General Universitario de Valencia

location_facility: ASST Grande Ospedale Metropolitano Niguarda

location_facility: Hiroshima City Hiroshima Citizens Hospital

location_facility: Uniwersytecki Szpital Kliniczny UM we Wroclawiu

location_facility: Clinical Oncological Dispensary of Omsk Region

location_facility: Sir Mortimer B. Davis Jewish General Hospital

location_facility: Niigata University Medical and Dental Hospital

location_facility: Krasnoyarsk Regional Clinical Oncology Dispensary

title: A Randomized, Open Label, Multicenter Phase 2/3 Study to Evaluate the Efficacy and Safety of Rogaratinib (BAY1163877) Compared to Chemotherapy in Patients With FGFR-positive Locally Advanced or Metastatic Urothelial Carcinoma Who Have Received Prior Platinum-containing Chemotherapy

summary:
This is a randomized, open-label, multicenter Phase 2/3 study to evaluate the efficacy and safety of rogaratinib (BAY 1163877) compared to chemotherapy in patients with FGFR-positive locally advanced or metastatic urothelial carcinoma who have received prior platinum-containing chemotherapy.

The primary objective is to demonstrate the superiority of rogaratinib over chemotherapy in terms of objective response rate (before: overall survivial) of urothelial carcinoma patients with FGFR positive tumors.

At randomization, patients will have locally advanced or metastatic urothelial carcinoma and have received at least one prior platinum-containing chemotherapy regimen. Only patients with FGFR1 or 3 positive tumors can be randomized into the study. Archival tumor tissue is adequate for testing of FGFR1 and 3 mRNA expressions, which will be determined centrally using an RNA in situ hybridization (RNA-ISH) test. Approximately 42 % of UC patients with locally advanced or metastatic UC are identified as FGFR-positive by the RNA-ISH cut-off applied.


title: A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Multicenter Study to Evaluate the Efficacy and Safety of Sotagliflozin in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Basal Insulin Alone or in Addition to Oral Antidiabetes Drugs (OADs)

acronym: SOTA-INS

summary:
Primary Objective:

To demonstrate the superiority of sotagliflozin 400 milligrams (mg) versus placebo with respect to hemoglobin A1C (HbA1c) reduction in participants with type 2 diabetes mellitus (T2D) who have inadequate glycemic control on basal insulin alone or with oral antidiabetes drugs (OADs).

Secondary Objectives:

To assess the effects of sotagliflozin 400 mg versus placebo on fasting plasma glucose (FPG), body weight, systolic blood pressure (SBP), and HbA1c.
To assess the effects of sotagliflozin 200 mg versus placebo on HbA1c, body weight, FPG, and SBP.
To evaluate the safety of sotagliflozin 400 and 200 mg versus placebo.

lead_sponsor: Lexicon Pharmaceuticals

location_country:
France
Czechia
Bulgaria
Slovakia
Hungary
United States
United Kingdom
Canada

location_facility:
Investigational Site Number 8406048
Investigational Site Number 8406043
Investigational Site Number 1006003
Investigational Site Number 8406054
Investigational Site Number 8406035
Investigational Site Number 2506003
Investigational Site Number 8406029
Investigational Site Number 1006005
Investigational Site Number 2506005
Investigational Site Number 8406032
Investigational Site Number 8406046
Investigational Site Number 8406040
Investigational Site Number 8406008
Investigational Site Number 2506008
Investigational Site Number 8406024
Investigational Site Number 2506012
Investigational Site Number 8406042
Investigational Site Number 8266001
Investigational Site Number 2036006
Investigational Site Number 1246004
Investigational Site Number 8406002
Investigational Site Number 8406004
Investigational Site Number 8266002
Investigational Site Number 8406010
Investigational Site Number 8406009
Investigational Site Number 7036007
Investigational Site Number 2506010
Investigational Site Number 8406011
Investigational Site Number 3486005
Investigational Site Number 2036002
Investigational Site Number 8406019
Investigational Site Number 7036010
Investigational Site Number 8406037
Investigational Site Number 7036006
Investigational Site Number 8406021
Investigational Site Number 3486003
Investigational Site Number 8406015
Investigational Site Number 1006010
Investigational Site Number 3486001
Investigational Site Number 1006006
Investigational Site Number 8406050
Investigational Site Number 3486006
Investigational Site Number 3486007
Investigational Site Number 2036001
Investigational Site Number 8406014
Investigational Site Number 3486009
Investigational Site Number 8406022
Investigational Site Number 2506011
Investigational Site Number 2036003
Investigational Site Number 1006007
Investigational Site Number 8406028
Investigational Site Number 8406030
Investigational Site Number 2506009
Investigational Site Number 8406013
Investigational Site Number 8406036
Investigational Site Number 8406018
Investigational Site Number 8406047
Investigational Site Number 2506004
Investigational Site Number 8266003
Investigational Site Number 2036007
Investigational Site Number 8406045
Investigational Site Number 8406053
Investigational Site Number 7036011
Investigational Site Number 2036008
Investigational Site Number 1246002
Investigational Site Number 2506002
Investigational Site Number 8406027
Investigational Site Number 8406023
Investigational Site Number 8406039
Investigational Site Number 8406038
Investigational Site Number 7036001
Investigational Site Number 7036009
Investigational Site Number 8406020
Investigational Site Number 2036005
Investigational Site Number 8406033
Investigational Site Number 7036004
Investigational Site Number 8406026
Investigational Site Number 8266004
Investigational Site Number 8406031
Investigational Site Number 8406001
Investigational Site Number 1006009
Investigational Site Number 1006004
Investigational Site Number 2506006
Investigational Site Number 8406005
Investigational Site Number 8266006
Investigational Site Number 1246005
Investigational Site Number 8406017
Investigational Site Number 1006002
Investigational Site Number 8406044
Investigational Site Number 7036003
Investigational Site Number 1246003
Investigational Site Number 7036005
Investigational Site Number 8406003
Investigational Site Number 3486008
Investigational Site Number 8406025
Investigational Site Number 3486002
Investigational Site Number 8406016
Investigational Site Number 8406006
Investigational Site Number 7036008
Investigational Site Number 2506007
Investigational Site Number 8406052
Investigational Site Number 8406034
Investigational Site Number 8406051
Investigational Site Number 1006001
Investigational Site Number 8266008
Investigational Site Number 1246001

status_simplified: Completed


ReferenceCitation: Guttman-Yassky E, Teixeira HD, Simpson EL, Papp KA, Pangan AL, Blauvelt A, Thaçi D, Chu CY, Hong HC, Katoh N, Paller AS, Calimlim B, Gu Y, Hu X, Liu M, Yang Y, Liu J, Tenorio AR, Chu AD, Irvine AD. Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials. Lancet. 2021 Jun 5;397(10290):2151-2168. doi: 10.1016/S0140-6736(21)00588-2. Epub 2021 May 21. Erratum in: Lancet. 2021 Jun 5;397(10290):2150.

family: Guttman-Yassky

full_name: Emma Guttman-Yassky

given: Emma

family: Teixeira

full_name: Henrique D Teixeira

given: Henrique D

family: Simpson

full_name: Eric L Simpson

given: Eric L

family: Papp

full_name: Kim A Papp

given: Kim A

family: Pangan

full_name: Aileen L Pangan

given: Aileen L

family: Blauvelt

full_name: Andrew Blauvelt

given: Andrew

family: Thaçi

full_name: Diamant Thaçi

given: Diamant

family: Chu

full_name: Chia-Yu Chu

given: Chia-Yu

family: Hong

full_name: H Chih-ho Hong

given: H Chih-ho

family: Katoh

full_name: Norito Katoh

given: Norito

family: Paller

full_name: Amy S Paller

given: Amy S

family: Calimlim

full_name: Brian Calimlim

given: Brian

family: Gu

full_name: Yihua Gu

given: Yihua

family: Hu

full_name: Xiaofei Hu

given: Xiaofei

family: Liu

full_name: Meng Liu

given: Meng

family: Yang

full_name: Yang Yang

given: Yang

full_name: John Liu

given: John

family: Tenorio

full_name: Allan R Tenorio

given: Allan R

full_name: Alvina D Chu

given: Alvina D

family: Irvine

full_name: Alan D Irvine

given: Alan D

journal_name: The Lancet

publisher: Elsevier BV

publisher_dissemination: Elsevier

publisher_group: Elsevier

publisher_normalized: Elsevier

ipd_sharing_description: AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols and clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.

lead_sponsor: AbbVie

location_country:
Finland
Malaysia
Romania
Australia
Russian Federation
Denmark
Ukraine
Croatia
France
Japan
Argentina
Canada
Turkey
Colombia
Switzerland
Bulgaria
Puerto Rico
China
Germany
United States
United Kingdom
Italy
Bosnia and Herzegovina
New Zealand
Estonia

acronym: Measure Up 1

location_facility: Clinical Center University of Sarajevo /ID# 202669

location_facility: Clinical Trials Management, LLC - Metairie /ID# 212659

location_facility: National Medical Research Center for Children's Health /ID# 203440

location_facility: Oregon Medical Res Center PC /ID# 200428

location_facility: Northern Care Alliance NHS Group /ID# 201194

location_facility: Ponce Medical School Foundation /ID# 201821

location_facility: Dermatology Physicians of Connecticut /ID# 200928

location_facility: Care Access Research - Walnut Creek /ID# 200940

location_facility: Istanbul University-Cerrahpasa, Cerrahpasa Medical Faculty /ID# 204100

location_facility: Azienda Ospedaliero Universitaria Ospedali Riuniti di Ancona /ID# 200692

location_facility: Union Hospital affiliated to Tongji Medical College of Huazhong University of Sc /ID# 208598

location_facility: Dr. Wei Jing Loo Medicine Prof /ID# 206051

location_facility: Integrated Dermatology of Massachusetts, LLC /ID# 209468

location_facility: CHUV, Centre hospitalier universitaire vaudois /ID# 200910

location_facility: Peking University People's Hospital /ID# 202549

location_facility: Northwestern University Feinberg School of Medicine /ID# 201644

location_facility: Dre Angelique Gagne-Henley M.D. inc. /ID# 200326

location_facility: Dermdox Dermatology Centers, PC /ID# 213782

location_facility: Florida International Rsrch cr /ID# 218507

location_facility: Herlev and Gentofte Hospital /ID# 200736

location_facility: Kyushu Central Hospital of the Mutual Aid Association of Public School Teachers /ID# 202891

location_facility: Oregon Health and Science University /ID# 200992

location_facility: Lynn Health Science Institute (LHSI) /ID# 212676

location_facility: Holdsworth House Medical Practice /ID# 211236

location_facility: Clinical Trials Management, LLC - Covington /ID# 212658

location_facility: CHU de Nantes, Hotel Dieu -HME /ID# 206377

location_facility: Allergy & Asthma Associates of Southern California /ID# 200733

location_facility: Center for Clinical Studies - Webster TX /ID# 203185

location_facility: Duplicate_Klinikum rechts der Isar - Technische Universitaet Muenchen /ID# 202087

location_facility: Derm & Laser Ctr of Charleston /ID# 200402

location_facility: Fundacion Hospital San Vicente de Paul - Rionegro /ID# 202043

location_facility: A.O.U. di Bologna Policlinico S.Orsola-Malpighi /ID# 200746

location_facility: Universitaetsklinikum Schleswig-Holstein Campus Kiel /ID# 202255

location_facility: Massachusetts General Hospital /ID# 200474

location_facility: DUP_Spitalul Clinic Colentina /ID# 205860

location_facility: CHUV, Centre hospitalier universitaire vaudois /ID# 206505

location_facility: California Allergy and Asthma Medical Group /ID# 200727

location_facility: Duplicate_Klinicki bolnicki centar Osijek /ID# 201523

location_facility: Psoriahue Med Interdisciplinar /ID# 202451

location_facility: Hôpitaux Universitaires Genève /ID# 201600

location_facility: Dr. David Gratton Dermat Inc. /ID# 200309

location_facility: Ural Research Institute of dermatovenerology and immunopathology /ID# 201593

location_facility: Azienda Ospedaliera Universitaria Federico II /ID# 200750

location_facility: North Estonia Medical Centre /ID# 200951

location_facility: Medizinische Hochschule Hannover /ID# 202091

location_facility: Integrated Clinical Research LLC /ID# 200900

location_facility: Fondazione PTV Policlinico Tor Vergata /ID# 201136

location_facility: Ruijin Hospital, Shanghai Jiaotong University School of Medicine /ID# 202554

location_facility: University of Yamanashi Hospital /ID# 204174

location_facility: Modern Research Associates, PL /ID# 200705

location_facility: University Clinical Centre of the Republic of Srpska /ID# 202667

location_facility: Clin Res Inst of Michigan, LLC /ID# 208019

location_facility: Chelsea and Westminster Hospital NHS Foundation Trust9 /ID# 201971

location_facility: The South Bend Clinic Center /ID# 200371

location_facility: Forest Hills Dermatology Group /ID# 209244

location_facility: Klinicki bolnicki centar Split /ID# 201527

location_facility: Clear Dermatology & Aesthetics Center /ID# 201256

location_facility: Hopital Saint Vincent de Paul /ID# 218253

location_facility: North Eastern Health Specialists /ID# 205802

location_facility: Fundacion Centro de Excelencia en Enfermedades Cronicas no Transmisibles - FUNCE /ID# 201905

location_facility: West Middlesex University Hospital /ID# 202273

location_facility: Guy's and St Thomas' NHS Foundation Trust /ID# 201192

location_facility: Gazi Universitesi Tip Fakultes /ID# 204176

location_facility: Icahn School of Medicine at Mount Sinai /ID# 200370

location_facility: Bispebjerg and Frederiksberg Hospital /ID# 200979

location_facility: UMHAT Professor Stoyan Kirkovich /ID# 201522

location_facility: Sun Yat-sen Memorial Hospital of Sun Yat-sen University /ID# 208597

location_facility: UMHAT Dr Georgi Stranski EAD /ID# 201521

location_facility: CMS3 Company for Medical Study /ID# 205193

location_facility: The second Affiliated hospital of Zhejiang University school of Medicine /ID# 202608

location_facility: San Luis Derm and Laser Clinic /ID# 200372

location_facility: Instituto de Neumonología y Dermatología /ID# 203444

location_facility: Aichi Medical University Hospital /ID# 202833

location_facility: Duplicate_George Washington Univ Med /ID# 200364

location_facility: Confido Private Medical Clinic /ID# 200846

location_facility: Universitaetsklinikum Frankfurt /ID# 202089

location_facility: Arlington Research Center, Inc /ID# 200391

location_facility: Advanced Dermatology of the Midlands /ID# 201689

location_facility: Leavitt Medical Associates of Florida /ID# 200880

location_facility: Hamilton Health Sciences - McMaster University Medical Centre /ID# 200313

location_facility: Dermatology Research Institute Inc. /ID# 200318

location_facility: Alliance Dermatology and MOHs /ID# 200375

location_facility: Multi-Speciality Research Associates /ID# 213254

location_facility: Peking University Third Hospital /ID# 202612

location_facility: Saratov State Medical University n.a. V.I. Razumovskiy /ID# 201595

location_facility: Universitaetsmedizin der Johannes Gutenberg-Universitaet Mainz /ID# 205192

location_facility: The First Hospital of China Medical University /ID# 202615

location_facility: Ctr Int de Reum del Caribe SAS /ID# 201620

location_facility: Military Hospital of Military-Medical Clinical Center of Southern Region /ID# 201962

location_facility: Hacettepe University Faculty of Medicine /ID# 204099

location_facility: Klinika za dječje bolesti Zagreb /ID# 203151

location_facility: Bakersfield Derma & Skin Cance /ID# 200433

location_facility: Chelyabinsk Regional Clinical Dermatovenerologic Dispensary /ID# 201996

location_facility: Clinical Research Puerto Rico /ID# 203309

location_facility: CHU Toulouse - Hopital Larrey /ID# 201528

location_facility: A.O.U. Policlinico G. Rodolico S.Marco- Presidio G.Rodolico /ID# 200741

location_facility: Wiseman Dermatology Research /ID# 200323

location_facility: The Third Affiliated Hospital Of Sun Yat-Sen University /ID# 202548

location_facility: ME "Rivne Regional Dermatology and Venereology Dispensary" of RRC /ID# 210504

location_facility: Inselspital, Universitätsspital Bern /ID# 201598

location_facility: Clinical Research Consortium /ID# 200734

location_facility: Clinical Center University of Sarajevo /ID# 202668

location_facility: University Hospital Kyoto Prefectural University of Medicine /ID# 201876

location_facility: Cabinet Medical de Dermatovenerologie Dr. Remus Orasan /ID# 205862

location_facility: Erciyes University Medical Fac /ID# 204098

location_facility: Universitaetsklinikum Muenster /ID# 202085

location_facility: Clinical Dermatovenerology Dispensary /ID# 203439

location_facility: Klinicki bolnicki centar Zagreb /ID# 201879

location_facility: Hospital Raja Permaisuri Bainun /ID# 204375

location_facility: Huashan Hospital of Fudan University /ID# 205760

location_facility: University Clinical Centre of the Republic of Srpska /ID# 202666

location_facility: Dr. Chih-ho Hong Medical Inc. /ID# 200311

location_facility: Dermatology Ottawa Research Centre /ID# 200319

location_facility: Dermatology Specialists of Spokane /ID# 202068

location_facility: Azienda Ospedaliero Universitaria Pisana-Stabilimento di Santa Chiara /ID# 200695

location_facility: Klinicki bolnicki centar Rijeka /ID# 217423

title: A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Upadacitinib in Adolescent and Adult Subjects With Moderate to Severe Atopic Dermatitis

summary: The objective of this study is to assess the efficacy and safety of upadacitinib for the treatment of adolescent and adult participants with moderate to severe Atopic Dermatitis (AD) who are candidates for systemic therapy.


title: A Randomized Phase 3 Study to Evaluate the Efficacy and Safety of Daratumumab in Combination With Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) Compared to CyBorD Alone in Newly Diagnosed Systemic AL Amyloidosis

summary: The purpose of this study is to evaluate the efficacy and safety of daratumumab plus cyclophosphamide, bortezomib and dexamethasone (CyBorD) compared with CyBorD alone in treatment of newly diagnosed amyloid light chain (AL) amyloidosis participants.

ReferenceCitation: Kastritis E, Palladini G, Minnema MC, Wechalekar AD, Jaccard A, Lee HC, Sanchorawala V, Gibbs S, Mollee P, Venner CP, Lu J, Schönland S, Gatt ME, Suzuki K, Kim K, Cibeira MT, Beksac M, Libby E, Valent J, Hungria V, Wong SW, Rosenzweig M, Bumma N, Huart A, Dimopoulos MA, Bhutani D, Waxman AJ, Goodman SA, Zonder JA, Lam S, Song K, Hansen T, Manier S, Roeloffzen W, Jamroziak K, Kwok F, Shimazaki C, Kim JS, Crusoe E, Ahmadi T, Tran N, Qin X, Vasey SY, Tromp B, Schecter JM, Weiss BM, Zhuang SH, Vermeulen J, Merlini G, Comenzo RL; ANDROMEDA Trial Investigators. Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis. N Engl J Med. 2021 Jul 1;385(1):46-58. doi: 10.1056/NEJMoa2028631.

name: From the Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Athens (E.K., M.A.D.); the Amyloidosis Research and Treatment Center, Fondazione IRCCS Policlinico San Matteo, and the Department of Molecular Medicine, University of Pavia, Pavia, Italy (G.P., G.M.); the Department of Hematology, University Medical Center Utrecht, University Utrecht, Utrecht (M.C.M.), the Amyloidosis Center of Expertise, University of Groningen, University Medical Center...

family: Kastritis

full_name: Efstathios Kastritis

given: Efstathios

family: Palladini

full_name: Giovanni Palladini

given: Giovanni

family: Minnema

full_name: Monique C. Minnema

given: Monique C.

family: Wechalekar

full_name: Ashutosh D. Wechalekar

given: Ashutosh D.

family: Jaccard

full_name: Arnaud Jaccard

given: Arnaud

family: Lee

full_name: Hans C. Lee

given: Hans C.

family: Sanchorawala

full_name: Vaishali Sanchorawala

given: Vaishali

family: Gibbs

full_name: Simon Gibbs

given: Simon

family: Mollee

full_name: Peter Mollee

given: Peter

family: Venner

full_name: Christopher P. Venner

given: Christopher P.

family: Lu

full_name: Jin Lu

given: Jin

family: Schönland

full_name: Stefan Schönland

given: Stefan

family: Gatt

full_name: Moshe E. Gatt

given: Moshe E.

family: Suzuki

full_name: Kenshi Suzuki

given: Kenshi

family: Kim

full_name: Kihyun Kim

given: Kihyun

family: Cibeira

full_name: M. Teresa Cibeira

given: M. Teresa

family: Beksac

full_name: Meral Beksac

given: Meral

family: Libby

full_name: Edward Libby

given: Edward

family: Valent

full_name: Jason Valent

given: Jason

family: Hungria

full_name: Vania Hungria

given: Vania

family: Wong

full_name: Sandy W. Wong

given: Sandy W.

family: Rosenzweig

full_name: Michael Rosenzweig

given: Michael

family: Bumma

full_name: Naresh Bumma

ReferenceCitation: Palladini G, Kastritis E, Maurer MS, Zonder J, Minnema MC, Wechalekar AD, Jaccard A, Lee HC, Bumma N, Kaufman JL, Medvedova E, Kovacsovics T, Rosenzweig M, Sanchorawala V, Qin X, Vasey SY, Weiss BM, Vermeulen J, Merlini G, Comenzo RL. Daratumumab plus CyBorD for patients with newly diagnosed AL amyloidosis: safety run-in results of ANDROMEDA. Blood. 2020 Jul 2;136(1):71-80. doi: 10.1182/blood.2019004460.

name: Amyloidosis Research and Treatment Center, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Policlinico San Matteo, Pavia, Italy;

name: Department of Molecular Medicine, University of Pavia, Pavia, Italy;

name: Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece;

name: Columbia University Irving Medical Center, New York, NY;

name: Barbara Ann Karmanos Cancer Institute, Detroit, MI;

name: Department of Hematology, University Medical Center Utrecht, Utrecht, The Netherlands;

name: Division of Medicine, Faculty of Medical Sciences, University College London, London, United Kingdom;

name: Centre Hospitalier Universitaire and Reference Center for AL Amyloidosis, Limoges, France;

name: Division of Cancer Medicine, Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX;

name: Division of Hematology, The Ohio State University Comprehensive Cancer Center, Columbus, OH;

name: Winship Cancer Institute, Emory University, Atlanta, GA;

name: Oregon Health & Science University, Portland, OR;

name: Division of Hematology and Hematologic Malignancies, University of Utah School of Medicine, and the Huntsman Cancer Institute, Salt Lake City, UT;

name: Department of Hematology and Hematopoietic Cell Transplantation, Judy and Bernard Briskin Center for Multiple Myeloma Research, City of Hope, Duarte, CA;

name: Department of Medicine and Amyloidosis Center, Boston University School of Medicine and Boston Medical Center, Boston, MA;

name: Janssen Research & Development, LLC, Spring House, PA;

name: Janssen Research & Development, Leiden, The Netherlands; and

name: Division of Hematology/Oncology, John C. Davis Myeloma and Amyloid Program, Tufts Medical Center, Boston, MA

evidence: oa repository (via OAI-PMH title and first author match)

repository_institution: University College London - UCL Discovery

location_country:
Greece
Belgium
Australia
Denmark
France
Japan
Poland
Canada
Korea, Republic of
Sweden
Netherlands
Hungary
China
United States
Germany
United Kingdom
Italy
Brazil
Mexico
Israel
Spain
Turkey

location_facility: University Health Network (UHN) Princess Margaret Cancer Centre

location_facility: Ankara Universitesi Tip Fakultesi Cebeci Hastanesi

location_facility: Instituto COI de Pesquisa, Educacao e Gestao

location_facility: Istituto di Ematologia Seràgnoli azienda ospedaliera univeristaria Policlinico S.Orsola-Malpighi

location_facility: Wake Forest University Health Sciences - Cardiovascular Medicine

location_facility: First affiliated Hospital of Zhejiang University

location_facility: Sociedade Pernambucana de Combate ao Cancer

location_facility: Severance Hospital, Yonsei University Health System

location_facility: Hospital de Base de São José do Rio Preto

location_facility: Winship Cancer Institute Emory University

location_facility: Dipartimento Di Biotecnologie Cellulari Ed Ematologia-Università ''La Sapienza'',Policlinico Umberto I

location_facility: National Hospital Organization Okayama Medical Center

location_facility: Dél-pesti Centrumkórház - Országos Hematológiai és Infektológiai Intézet, Szent László Telephely

location_facility: Universitätsklinikum Würzburg Med. Klinik U. Poliklinik Ii

location_facility: Universitaetsklinikum Heidelberg Medizinische Klinik V

location_facility: Ondokuz Mayis Universitesi Tip Fakultesi

location_facility: Samodzielny Publiczny Zaklad Opieki Zdrowotnej Zespol Szpitali Miejskich

location_facility: Washington University School of Medicine

location_facility: The Catholic University of Korea, Seoul St. Mary's Hospital

location_facility: University of Pennsylvania Medical Center

location_facility: The First Affiliated Hospital of Wenzhou Medical University

location_facility: Universitaetsklinikum Tuebingen der Eberhard-Karls-Universitaet, Abteilung fuer Innere Medizin II,

location_facility: A.O.U. Città della Salute e della Scienza

location_facility: Semmelweis Egyetem I.Belgyogyaszati Klinika

location_facility: University Hospitals Birmingham NHS Trust,

location_facility: Istanbul University Istanbul Medical Faculty

location_facility: HOPA-Hämatologisch-Onkologische Praxis Altona MVZ GmbH

location_facility: Hiroshima Red Cross Hospital & Atomic-bomb Survivors Hospital

location_facility: Centro de Investigación Farmacéutica Especializada

location_facility: Hospital Universitario 'Dr. Jose Eleuterio Gonzalez'

location_facility: Ruijin Hospital, Shanghai Jiao Tong University

location_facility: University of Texas, MD Anderson Cancer Center


ReferenceCitation: Bhak RH, Mody-Patel N, Baver SB, Kunzweiler C, Yee CW, Sundaresan S, Swartz N, Duh MS, Krishnan S, Sarda SP. Comparative effectiveness of pegcetacoplan versus ravulizumab in patients with paroxysmal nocturnal hemoglobinuria previously treated with eculizumab: a matching-adjusted indirect comparison. Curr Med Res Opin. 2021 Nov;37(11):1913-1923. doi: 10.1080/03007995.2021.1971182. Epub 2021 Sep 3.

family: Bhak

full_name: Rachel H. Bhak

given: Rachel H.

name: Apellis Pharmaceuticals, Inc, Waltham, MA, USA

family: Mody-Patel

full_name: Nikita Mody-Patel

given: Nikita

family: Baver

full_name: Scott B. Baver

given: Scott B.

family: Kunzweiler

full_name: Colin Kunzweiler

given: Colin

family: Yee

full_name: Christopher W. Yee

given: Christopher W.

family: Sundaresan

full_name: Sanjana Sundaresan

given: Sanjana

family: Swartz

full_name: Natalia Swartz

given: Natalia

family: Duh

full_name: Mei Sheng Duh

given: Mei Sheng

family: Krishnan

full_name: Sangeeta Krishnan

given: Sangeeta

family: Sarda

full_name: Sujata P. Sarda

given: Sujata P.

journal_name: Current Medical Research and Opinion

oa_host_type: publisher

license: cc-by-nc-nd

license_normalized: cc-by-nc-nd

publisher: Informa UK Limited

publisher_dissemination: Informa

publisher_group: Informa

publisher_normalized: Informa

ReferenceCitation: Hillmen P, Szer J, Weitz I, Röth A, Höchsmann B, Panse J, Usuki K, Griffin M, Kiladjian JJ, de Castro C, Nishimori H, Tan L, Hamdani M, Deschatelets P, Francois C, Grossi F, Ajayi T, Risitano A, Peffault de la Tour R. Pegcetacoplan versus Eculizumab in Paroxysmal Nocturnal Hemoglobinuria. N Engl J Med. 2021 Mar 18;384(11):1028-1037. doi: 10.1056/NEJMoa2029073.

name: From the Department of Haematology, St. James’s University Hospital, Leeds (P.H., M.G.), and Lisa Tan Pharma Consulting, Cambridge (L.T.) — both in the United Kingdom; the Department of Clinical Haematology, Peter MacCallum Cancer Center and Royal Melbourne Hospital, Melbourne, VIC, Australia (J.S.); Jane Anne Nohl Division of Hematology, Keck School of Medicine of USC, Los Angeles (I.W.); the Department of Hematology, West German Cancer Center University Hospital Essen, University of Duisburg-Essen,...

family: Hillmen

full_name: Peter Hillmen

family: Szer

full_name: Jeff Szer

given: Jeff

family: Weitz

full_name: Ilene Weitz

given: Ilene

family: Röth

full_name: Alexander Röth

given: Alexander

family: Höchsmann

full_name: Britta Höchsmann

given: Britta

family: Panse

full_name: Jens Panse

given: Jens

family: Usuki

full_name: Kensuke Usuki

given: Kensuke

family: Griffin

full_name: Morag Griffin

given: Morag

family: Kiladjian

full_name: Jean-Jacques Kiladjian

given: Jean-Jacques

family: de Castro

full_name: Carlos de Castro

given: Carlos

family: Nishimori

full_name: Hisakazu Nishimori

given: Hisakazu

repository_institution: Okayama University - Okayama University Scientific Achievement Repository

location_country:
United States
Germany
France
Japan
Belgium
Australia
Russian Federation
Spain
Canada
United Kingdom
Korea, Republic of

location_facility: Investigative Clinical Research of Indiana

location_facility: Pavlov First Saint Petersburg State Medical University of Russian Ministry of Health

location_facility: Centre Hospitalier Universitaire de Lille

location_facility: Soonchunhyang University Bucheon Hospital

location_facility: Institut Universitaire du Cancer Toulouse - Oncopole

location_facility: Hospital Universitario Politécnico La Fe

location_facility: Cancer & Hematology Centers of Western Michigan

location_facility: St. James' Institute of Oncology, Leeds Teaching Hospitals

location_facility: Winship Cancer Institute of Emory University

location_facility: Institution of Health Care of Tyumen Region

location_facility: Hospital Universitario de Gran Canaria Dr. Negrín

location_facility: Japanese Red Cross Nagoya Daiichi Hospital

location_facility: Japanese Red Cross Nagoya Daini Hospital

title: A Phase III, Randomized, Multi-Center, Open-Label, Active-Comparator Controlled Study to Evaluate the Efficacy and Safety of APL-2 in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)

summary: Evaluation of the Efficacy and Safety of APL-2 in Patients with Paroxysmal Nocturnal Hemoglobinuria


title: A Phase III, Randomized, Multicenter, Open-Label, Two-Arm Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Patients With HER2-Positive Early Breast Cancer

acronym: FeDeriCa

summary: This is a global Phase III, two-arm, open-label, multicenter, randomized study to investigate the pharmacokinetics, efficacy, and safety of the fixed-dose combination (FDC) of pertuzumab and trastuzumab for subcutaneous (SC) administration in combination with chemotherapy in patients with human epidermal growth factor receptor 2 (HER2)-positive early breast cancer in the neoadjuvant/adjuvant setting.

ReferenceCitation: Tan AR, Im SA, Mattar A, Colomer R, Stroyakovskii D, Nowecki Z, De Laurentiis M, Pierga JY, Jung KH, Schem C, Hogea A, Badovinac Crnjevic T, Heeson S, Shivhare M, Kirschbrown WP, Restuccia E, Jackisch C; FeDeriCa study group. Fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection plus chemotherapy in HER2-positive early breast cancer (FeDeriCa): a randomised, open-label, multicentre, non-inferiority, phase 3 study. Lancet Oncol. 2021 Jan;22(1):85-97. doi: 10.1016/S1470-2045(20)30536-2. Epub 2020 Dec 21. Erratum in: Lancet Oncol. 2021 Feb;22(2):e42.

family: Tan

full_name: Antoinette R Tan

given: Antoinette R

family: Im

full_name: Seock-Ah Im

given: Seock-Ah

family: Mattar

full_name: André Mattar

given: André

family: Colomer

full_name: Ramon Colomer

given: Ramon

family: Stroyakovskii

full_name: Daniil Stroyakovskii

given: Daniil

family: Nowecki

full_name: Zbigniew Nowecki

given: Zbigniew

family: De Laurentiis

full_name: Michelino De Laurentiis

given: Michelino

family: Pierga

full_name: Jean-Yves Pierga

given: Jean-Yves

family: Jung

full_name: Kyung Hae Jung

given: Kyung Hae

family: Schem

full_name: Christian Schem

given: Christian

family: Hogea

full_name: Alexandra Hogea

given: Alexandra

family: Badovinac Crnjevic

full_name: Tanja Badovinac Crnjevic

given: Tanja

family: Heeson

full_name: Sarah Heeson

given: Sarah

family: Shivhare

full_name: Mahesh Shivhare

given: Mahesh

family: Kirschbrown

full_name: Whitney P Kirschbrown

given: Whitney P

family: Restuccia

full_name: Eleonora Restuccia

given: Eleonora

family: Jackisch

full_name: Christian Jackisch

journal_name: The Lancet Oncology

ipd_sharing_description:
Qualified researchers may request access to individual patient level data through the request platform (www.vivli.org). Further details on Roche's criteria for eligible studies are available here (https://vivli.org/ourmember/roche/).

For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm).

lead_sponsor: Hoffmann-La Roche

location_country:
Italy
United States
Brazil
Mexico
Germany
France
Czechia
Japan
Poland
Thailand
Belgium
Argentina
Russian Federation
Spain
Canada
United Kingdom
Korea, Republic of
Taiwan
Ukraine

location_facility: Chemotherapy SI Dnipropetrovsk MA of MOHU

location_facility: Institut Catala d Oncologia Hospital Duran i Reynals

location_facility: Klinikum Essen-Mitte Ev. Huyssens-Stiftung / Knappschafts GmbH; Klinik für Senologie / Brustzentrum

location_facility: National Hospital Organization Kyushu Cancer Center

location_facility: Istituto Nazionale Tumori Irccs Fondazione g. PASCALE;U.O.C. Oncologia Medica Senologica

location_facility: Municipal Noncommercial Institution Regional Center of Oncology

location_facility: IOV - Istituto Oncologico Veneto - IRCCS; Oncologia Medica II

location_facility: Complejo Hospitalario Universitario de Santiago (CHUS) ; Servicio de Oncologia

location_facility: Centro Oncologico Riojano Integral (CORI)

location_facility: Lakeridge Health Center; R. S. MacLaughlin Durham Regional Cancer Center

location_facility: Arkhangelsk Regional Clinical Oncology Dispensary

location_facility: RCI Sumy Regional Clinical Oncological Dispensary

location_facility: VETERANS GENERAL HOSPITAL; Department of General Surgery

location_facility: Hospital Clinico Universitario de Valencia; Servicio de Onco-hematologia

location_facility: Centre Hospitalier Universitaire de Sherbrooke - Hopital Fleurimont

location_facility: Moscow city oncology hospital #62 of Moscow Healthcare Department

location_facility: G.Sund Gynäkologie Kompetenzzentrum; Praxis Dr. med. Carsten Hielscher

location_facility: China Medical University Hospital; Surgery

location_facility: Narodowy Inst.Onkologii im.Sklodowskiej-Curie Panstw.Inst.Bad; Klinika Nowtw.Piersi i Chir.Rekonstr

location_facility: Hospital Universitario 12 de Octubre; Servicio de Oncologia

location_facility: Clinical Oncology Dispensary of Ministry of Health of Tatarstan

location_facility: Saitama Medical University International Medical Center

location_facility: National Cancer Institute MOH of Ukraine

location_facility: Songklanagarind Hospital; Department of Surgery

location_facility: S-Pb clinical scientific practical center of specialized kinds of medical care (oncological)

location_facility: Sana Klinikum Offenbach GmbH; Klinik für Gynäkologie & Geburtshilfe

location_facility: Seoul National University Bundang Hospital

location_facility: Hiroshima City Hiroshima Citizens Hospital

location_facility: Hospital Universitario Reina Sofia; Servicio de Oncologia

location_facility: Hochwaldkrankenhaus; Abt.Gynäkologie Geburtshilfe u.Senologie

location_facility: Fundación CENIT para la Investigación en Neurociencias

location_facility: Hospital de Cruces; Servicio de Oncología Médica

location_facility: Maharaj Nakorn Chiang Mai Hospital; Department of Surgery/Head Neck and Breast Unit; Clinical Trial

location_facility: Università degli Studi Federico II; Clinica di Oncologia Medica

location_facility: Uni Degli Studi Di Genova ; Clinica Di Medicina Interna Ad Indirizzo Oncologico

location_facility: Irccs Centro Di Riferimento Oncologico (CRO); Dipartimento Di Oncologia Medica

location_facility: Hospital Universitario Virgen del Rocio; Servicio de Oncologia

location_facility: Chang Gung Medical Foundation - Linkou; Dept of Surgery

location_facility: Narodowy Inst.Onkol.im.Sklodowskiej-Curie Panstw.Inst.Bad Gliwice; Centr.Diagn.i Lecz.Chor.Piersi

location_facility: St Georges University Hospitals NHS Foundation Trust

location_facility: Omsk Region Clinical Oncology Dispensary; 1St Sergical Department

location_facility: Zachodniopomorskie Centrum Onkologii, Osrodek Innowacyjnosci, Rozwoju i Badan Klinicznych

location_facility: Bialostockie Centrum Onkologii im. Marii Sklodowskiej - Curie

location_facility: National Hospital Organization Hokkaido Cancer Center

location_facility: Faculty of Med. Siriraj Hosp.; Med.-Div. of Med. Oncology

location_facility: Lviv State Oncology Regional Treatment and Diagnostic Centre

location_facility: Kooperatives Mammazentrum Hamburg Krankenhaus Jerusalem

location_facility: Hospital Araujo Jorge; Departamento de Ginecologia E Mama

intervention_type: Radiation


intervention_type: Biological

lead_sponsor: Bristol-Myers Squibb

location_country:
Finland
Greece
Romania
Australia
Belgium
Russian Federation
Denmark
France
Poland
Norway
Argentina
Canada
Colombia
Chile
Sweden
Germany
United States
United Kingdom
Italy
Austria
Brazil
Mexico
Israel
New Zealand
Spain

location_facility: Oddzial Onkologii Klinicznej i Doswiadczalnej

location_facility: Azienda Ospedaliera Città della Salute e della Scienza di Torino

location_facility: Sidney Kimmel Comprehensive Cancer Center At Johns Hopkins

location_facility: Medizinische Hochschule Hannover (Hannover Medical School)

location_facility: ASST Papa Giovanni XXIII - Azienda Ospedaliera Papa Giovanni XXIII

location_facility: Northwestern University Feinberg School of Medicine

location_facility: H & J Weinberg Can Int @ Franklin Square

location_facility: Fort Wayne Medical Oncology and Hematology

location_facility: Istituto Nazionale Tumori Fondazione Pascale

location_facility: Sansum Santa Barbara Medical Foundation Clinic

title: A Randomized, Double-Blind Phase 2/3 Study of Relatlimab Combined With Nivolumab Versus Nivolumab in Participants With Previously Untreated Metastatic or Unresectable Melanoma

summary: The purpose of this study is to determine whether relatlimab in combination with nivolumab is more effective than nivolumab by itself in treating unresectable melanoma or melanoma that has spread.


location_country:
Peru
Belgium
Australia
Russian Federation
Denmark
Taiwan
France
Japan
Poland
Norway
Argentina
Canada
Korea, Republic of
Turkey
South Africa
Sweden
China
Portugal
Germany
United States
United Kingdom
Italy
Brazil
Serbia
Israel
Spain
Estonia

acronym: CREAD 2

location_facility: Hospital Geral de Santo Antonio; Servico de Neurologia

location_facility: PANAKEIA - Arzneimittelforschung Leipzig GmbH

location_facility: Tel Aviv Sourasky Medical Center; Department of Neurology

location_facility: University of Cincinnati; Department of Psychiatry and Behavioral Neuroscience

location_facility: Akershus universitetssykehus HF; Nevroklinikken S203

location_facility: National Hospital Organization Sagamihara National Hospital

location_facility: Klinikum Joh.Wolfg.Goethe-UNI Zentrum d. Psychiatrie Klinik f. Psychiatrie Psychosomatik

location_facility: Istanbul University Istanbul School of Medicine; Neurology

location_facility: CHU de Limoges Hopital Dupuytren; Service de Medecine Geriatrique

location_facility: Sheba Medical Center; Psychiatry Department

location_facility: Klinikum rechts der Isar der TU München; Klinik für Psychiatrie und Psychotherapie

location_facility: IRCCS Ospedale San Raffaele; Centro Disturbi della Memoria

location_facility: Skånes Universitetssjukhus Malmö, Minneskliniken

location_facility: Chang Gung Memorial Foundation - Linkou - Neurology

location_facility: NHS Lothian - Western General Hospital; NHS Lothian - Western General Hospital

location_facility: Surrey and Borders NHS Foundation Trust; Brain Science Research Unit

location_facility: Sussex Partnership NHS Foundation Trust; Cognitive Treatment and Research unit

location_facility: Tianjin Medical University General Hospital

location_facility: The Cognitive and Research Center of New Jersey

location_facility: Irccs Multimedica Santa Maria; Unita' Di Neurologia

location_facility: Fondazione IRCCS Istituto Nazionale Neurologico Besta; UO Neuropatologia

location_facility: Neurology clinic, Clinical Center of Serbia

location_facility: Hospital Universitario Marques de Valdecilla; Servicio de Neurología

location_facility: Ospedale San Giovanni Calibita Fatebenefratell;Neurologia

location_facility: Neuropsychiatric Research; Center of Southwest Florida

location_facility: Hospital Universitario Reina Sofia; Servicio de Neurologia

location_facility: Hacettepe University Medical Faculty; Neurology

location_facility: Alzheimer's Research and Treatment Center

location_facility: NHO Shizuoka Institute of Epilepsy and Neurological Disorders

location_facility: Universitätsklinikum Freiburg, Zentrum für Geriatrie und Gerontologie

location_facility: Taipei Medical University - Shuang Ho Hospital - Neurology

location_facility: ECRC Experimental and Clinical Research Center, Charité Campus Berlin Buch, Memory Clinic

location_facility: Hospital Pedro Hispano; Servico de Neurologia

location_facility: Complejo Asistencial Universitario de Salamanca; Servicio de Psiquiatría; CSM La Alamedilla

location_facility: National Clinical Research Inc.-Richmond

location_facility: Hospital Universitario Virgen Macarena; Servicio de Neurologia

location_facility: Charing Cross Hospital; Imperial Memory Unit, Level 10 West

location_facility: Clinic for Mental disorders Dr Laza Lazarevic

location_facility: National Hospital Organization Hiroshima-Nishi Medical Center

location_facility: Oslo universitetssykehus HF Ullevål sykehus; Hukommelsesklinikken

location_facility: Complejo Hospitalario Universitario de Santiago (CHUS) ; Servicio de Neurologia

location_facility: Umberto I Policlinico di Roma-Università di Roma La Sapienza

location_facility: KI Health Partners, LLC; New England Institute for Clinical Research

location_facility: Sahlgrenska Academy University,Neuroscience and Physiology;Departmt of Psychiatry and Neurochemistry

location_facility: Hopital Roger Salengro; Service de Neurologie

location_facility: Cleveland Clinic Lou Ruvo; Center for Brain Research

location_facility: Universitätsklinikum des Saarlandes Klinik f. Psychiatrie und Psychotherapie

location_facility: Hôpital de Jour du Centre pour Personnes Âgées; Louis Pasteur Neurologie

location_facility: Research Center for Clinical Studies, Inc.

location_facility: AO Città della Salute e della Scienza Osp.S.Giov.Battista Molinette; SC Geriatria

location_facility: Alzheimers Disease & Memory Disorders Center; Department of Neurology Baylor College of Medicine

location_facility: Institution of RAMS (Mental Health Research Center of RAMS)

location_facility: University of California, Davis; Alzheimers Disease Center, Department of Neurology

location_facility: State Autonomous Healthcare Institution "Republican Clinical Neurological Center

location_facility: IRCCS "Centro S. Giovanni di Dio" Fatebenefratelli -UO Alzheimer

location_facility: Seoul National University Bundang Hospital

location_facility: Hospital de Braga; Servico de Neurologia

location_facility: CHU de Rouen Hopital; Service de Neurologie

location_facility: National Hospital Organization Matsumoto Medical Center

location_facility: Hospital Ramon y Cajal; Servicio de Neurologia

location_facility: Tokyo Medical University Hachioji Medical Center

location_facility: Kawartha Centre - Redefining Healthy Aging

location_facility: Queen Elizabeth University Hospital; Clinical Research Facility

location_facility: St Nicolas Psychiatric Hospital; Chair of Psychiatry and Narcology of St. Petersburg Medical Academy

location_facility: Hospital General De Catalunya; Servicio de Neurologia

location_facility: Hospital Mutua De Terrasa; Servicio de Neurologia

location_facility: Kaohsiung Medical University Hospital; Neurology

location_facility: Hospital la Magdalena; Servicio de Neurologia

location_facility: Hornsby Ku-ring-gai Hospital; Division of Rehabilitation & Aged Care

location_facility: Azienda Ospedaliera Universitaria Policlinico Tor Vergata; Neurologia

location_facility: Policlínica Guipuzkoa; Servicio de Neurología

location_facility: Hospital San Pedro; Servicio de Neurología

location_facility: University of Nebraska Medical Center; Dept of Neurological Sciences

location_facility: Advanced Memory Research Institute of NJ

location_facility: Hospital Perpetuo Socorro, Servicio de Geriatria

location_facility: IRCCS Neuromed; Neurologia I-Centro studio e cura delle demenze e UVA

location_facility: Hospital General Universitario de Elche; Servicio de Neurología

location_facility: Clinic for neurology, Clinical Center Kragujevac

location_facility: State Healthcare Institution of Sverdlovsk Region Sverdlovsk Regional Clinical Psychiatric Hospita

location_facility: Health Partners Institute for Education and Research

location_facility: Aarhus Universitetshospital, Neurologisk Afdeling F, Demensklinikken

location_facility: State autonomous institution of healthcare Inter-regional clinical and diagnostic center

location_facility: Ospedale Casati Passirana di Rho; Centro Regionale Alzheimer

location_facility: The Fritchie Centre, Charlton Lane Centre, Charlon Lane, Leckhampton; The Fritchie Centre

location_facility: Clinica Internacional; Unidad De Investigacion

location_facility: Hospital Santa Caterina, Unitat de Valoració de la memoria i les demencies

location_facility: Hospital Nacional Dos de Mayo; Unidad de Investigacion de Neurologia

location_facility: National Center of Neurology and Psychiatry

location_facility: Clinica Universitaria de Navarra; Servicio de Neurología

location_facility: National Center for Geriatrics and Gerontology

location_facility: Hospital Quiron de Madrid; Servicio de Neurologia

location_facility: Hospital de la Santa Creu i Sant Pau; Servicio de Neurologia

location_facility: Hop Guillaume Et Rene Laennec; Cmrr St Herblain

location_facility: Hospital Virgen del Puerto. Servicio de Neurología

location_facility: National Taiwan University Hospital; Neurology

location_facility: Ohio State University; College of Medicine

location_facility: University Southampton NHS Foundation Trust; Wessex Neurologica Centre

location_facility: Ospedale S. Maria Nascente; Fondazione Don Gnocchi; Dip. Neurologia Riabilitativa

location_facility: Hospital Universitario de Burgos. Servicio de Neurología

location_facility: Private Practice; the Osteoporosis Clinic

location_facility: Ondokuz Mayis Univ. Med. Fac.; Neurology

title: A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy and Safety Study of Crenezumab in Patients With Prodromal to Mild Alzheimer's Disease

summary: This randomized, double-blind, placebo-controlled, parallel-group study will evaluate the efficacy and safety of crenezumab versus placebo in participants with prodromal to mild AD. Participants will be randomized 1:1 to receive either intravenous (IV) infusion of crenezumab or placebo every 4 weeks (Q4W) for 100 weeks. The primary efficacy assessment will be performed at 105 weeks. The participants who do not enter open-label extension will enter for a long term follow-up period for up to 52 weeks after the last crenezumab dose (Week 153).


title: A Phase 1 / 2, Open-Label, Multiple Ascending Dose Trial to Investigate the Safety, Tolerability, Pharmacokinetics, Biological, and Clinical Activity of AGEN2034 in Subjects With Metastatic or Locally Advanced Solid Tumors, With Expansion to Second Line Cervical Cancer

summary: This is a 2-part trial: a Phase 1, open-label, dose-escalation study in subjects with metastatic or locally advanced solid tumors, with a consecutive Phase 2 expansion to evaluate efficacy in subjects with recurrent, unresectable, or metastatic (advanced) cervical cancer that has progressed after a platinum-based treatment regimen.

lead_sponsor: Agenus Inc.

location_country:
Brazil
Chile
France
Poland
Belgium
Australia
Spain
Estonia
United States

location_facility: Centro de Investigación Del Cáncer James Lind

location_facility: Groupe Hospitalier Diaconesses Croix Saint-Simon - Hopital de la Croix Saint-Simon

location_facility: Swedish Medical Center-Cherry Hill Campus

location_facility: Robert H. Lurie Comprehensive Cancer Center of Northwestern University

location_facility: The University of Oklahoma Health Sciences Center

location_facility: Fundação Faculdade Regional de Medicina de São José do Rio Preto

location_facility: Florida Cancer Specialists & Research Institute

location_facility: University of Southern California - Keck School of Medicine

location_facility: The Ohio State University Comprehensive Cancer Center

location_facility: Institute de Cancerologie de l'Ouest (ICO) - René Gauducheau

location_facility: Instituto do Cancer do Estado de São Paulo

location_facility: The University of Texas MD Anderson Caner Center


lead_sponsor: Celgene

location_country:
Finland
Greece
Australia
Russian Federation
Taiwan
Ukraine
France
Poland
Lithuania
Slovakia
Canada
Slovenia
Korea, Republic of
South Africa
Sweden
Netherlands
Bulgaria
Hungary
China
Portugal
United States
Germany
Austria
Serbia
Israel
Georgia
Spain
Turkey

location_facility: Beijing YouYi Hospital-Beijing Friendship Hospital Capital Medical University

location_facility: Institute of Gastroenterology and Hepatology at Ha'Emek Medical Center

location_facility: Atlanta Center For Gastroenterology, P.C.

location_facility: UC Davis Health - Gastroenterology and Hepatology Clinical Trials Unit

location_facility: Centro Hospitalar do Alto Minho - Unidade Local de Saúde do Alto Minho, EPE

location_facility: N.N. Burdenko Penza Regional Clinical Hospital

location_facility: Polish Mother's Memorial Hospital - Research Institute

location_facility: Medical Scientific Manufacturing Association Dvizheniye Clinic

location_facility: Assistance Publique - Hopitaux de Paris - Hopital Beaujon

location_facility: Diagnostic and Consulting Center Alexandrovska

location_facility: City Clinical Hospital No 31 - St. Petersburg

location_facility: Mid America Gastrointestinal Consultants

location_facility: Health Centre Metabolic Diseases Outpatient Clinic in Wierzchoslawice

location_facility: Istanbul University Cerrahpasa Medical Faculty

location_facility: Odesa Regional Clinical Hospital Regional Gastroenterology Center Surgery Department

location_facility: Multiprofile Hospital for Active Treatment Tokuda Hospital Sofia

location_facility: Renji Hospital Affiliated to Shanghai Jiao Tong University School of Medicine

location_facility: General Hospital Djordje Jovanovic Zrenjanin

location_facility: Advance Clinical Research - Dayton Internal Medicine

location_facility: City Clinical Hospital n.a. V.M. Buyanov

location_facility: JSC Evex Medical Corporation - Telavi Referral Hospital

location_facility: Chang Gung Medical Foundation, Kaohsiung Memorial Hospital

location_facility: CHU Nantes University Hospital - Hotel Dieu Hospital

location_facility: Clinical Hospital Center Zvezdara Clinic of Internal Diseases

location_facility: Centro Hospitalar do Alto Ave, Hospital da Senhora da Oliveira Guimaraes

location_facility: Helsinki University Central Hospital (HUCH)

location_facility: JSC Evex Medical Corporation - Oncology Center

location_facility: University of Massachusetts Memorial Medical Center

location_facility: Cancer Care Associates of OK-N PorterAvenue

location_facility: University Clinical Hospital of Valencia

location_facility: Harvard Medical School - Boston Children's Hospital

location_facility: Joint Venture Company Diagnostic Center, Bioterm Ltd.

location_facility: Fejer Megyei Szent Gyorgy Egyetemi Oktato Korhaz

location_facility: Saint-Etienne University Hospital Center

location_facility: TWOJA PRZYCHODNIA Medical Centre of Szczecin LLC

location_facility: Helsicore - Israeli Georgian Medical Research Clinic

location_facility: Clinical Research Center Early-Phase Research Facility

location_facility: Clinical Center of Vojvodina, Clinic of Gastroenterology and Hepatology

location_facility: Medical Center Medical Clinic Blagomed LLC

location_facility: Multidisciplinary Clinic of the St. Nicholas, LLC

location_facility: Semmelweis Egyetem - Altalanos Orvostudomanyi Kar

location_facility: Johann Wolfgang Goethe University Hospital

location_facility: Vilnius University Hospital Santariskiu Klinikos

location_facility: Ohio State University Wexner Medical Center

location_facility: Istanbul Medeniyet Uni Goztepe Training&Res Hosp

location_facility: West Edmonton Gastroenterology Consultants

location_facility: Charite Universitaetsmedizin Berlin - Campus Benjamin Franklin

location_facility: Vrije Universiteit Medisch Centrum (VUMC)

location_facility: Non-Public Healthcare Facility Allmedica Clinical Trials

location_facility: Sotiria Chest Diseases Hospital of Athens

location_facility: Tongji Hospital, Tongji Medical College of Huazhong University of Science and Technology

location_facility: St. John Paul 2nd Municipal Hospital in Elblag

location_facility: University Hospital Marques de Valdecilla (HUMV)

location_facility: Csongrad County Dr. Bugyi Istvan Hospital

location_facility: Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University

location_facility: JSC Evex Medical Corporation - Batumi Referral Hospital

location_facility: Hospital of Lithuanian University of Health Sciences Kaunas Clinics

location_facility: Southern California Research Institute Medical Group, Inc.

location_facility: Ural State Medical Academy - Medical Association Novaya Bolnitsa

location_facility: JSC Infectious Disease, AIDS and Clinical Immunology Research Center

location_facility: Univerzitna nemocnica Bratislava, Nemocnica Ruzinov

location_facility: Allergy, Asthma and Immunology Center, PC

location_facility: Dnipropetrovsk II Mechnykov Regional Clinical Hospital Surgery Department 2

location_facility: I.I. Mechnikov North-Western State Medical University

location_facility: Petz Aladar Megyei Oktato Korhaz,II. Belgyogyaszat

location_facility: Clinical Hospital Center - Dr. Dragisa Misovic-Dedinje

location_facility: The Second Affiliated Hospital Of Zhengzhou University

location_facility: Euromed Multi-Specialty Center for Contemporary Medicine LLC

location_facility: Scientific Research Institute of Physiology and Basic Medicine

location_facility: Connecticut Clinical Research Foundation

location_facility: Jiangsu Province Hospital, The First Affiliated Hospital of Nanjing Medical University

location_facility: University Multiprofile Hospital for Active Treatment Tsaritsa Yoanna ISUL EAD

location_facility: BIK-KYIV Ukrainian German Gastroenterology Center

location_facility: Vilnius University Hospital Santariskes Clinics

location_facility: Henry Ford Medical Center - New Center One

location_facility: Clinical Hospital Center Bezanijska Kosa, Clinic of Internal Medicine

location_facility: General Hospital of Thessaloniki Hippokration

location_facility: University Hospital Puerta de Hierro Majadajonda

location_facility: LTD Academician N.Kipshidze Central University Clinic

location_facility: G.G. Kuvatov Republican Clinical Hospital

location_facility: Kindred Medical Institute for Clinical Trials, LLC

location_facility: The Seventh Medical Center of PLA General Hospital

location_facility: Hospital Universitario de Coimbra- Hospitais de Universidade de Coimbra

location_facility: Paramount Medical Research & Consulting, LLC

location_facility: Ivano-Frankivsk Regional Clinical Hospital

location_facility: Jan Mikulicz Radecki University Hospital

location_facility: Endoterapia PFG LLC, Endotherapy PFG Outpatient Clinic Branch No 1

location_facility: Hospital Universitario de Gran Canaria Dr. Negrin

location_facility: Vinnytsia M.I. Pyrohov Regional Clinical Hospital

location_facility: Universitaetsmedizin der Johannes Gutenberg-Universitaet Mainz

location_facility: World of the Health Inc. General Hospital Rimavska Sobota

location_facility: Sultan Abdulhamid Han Egitim ve Arastirma Hastanesi

location_facility: Military Medical Academy, Clinic of Gastroenterology and Hepatology

location_facility: Western Michigan University Homer Stryker M.D. School of Medicine

location_facility: Cotton ONeil Clinical Research Center Digestive Health

location_facility: John Hunter Hospital and Hunter Medical Research Institute

location_facility: DiGiovanna Institute for Medical Education And Research

location_facility: The First Affiliated Hospital of Nanchang University

location_facility: Gastroenterological Special Practice at Wittenbergplatz

location_facility: Zhangzhou Municipal Hospital of Fujian Province

location_facility: University of California at San Francisco

location_facility: Universitaetsklinikum Charite - Ruppiner Kliniken GmbH

location_facility: State Unitary Enterprise Passengeravtotrans

location_facility: A.N. Ryzhikh State Research Center for Coloproctology

location_facility: University Hospital of Girona Dr. Josep Trueta

location_facility: S.V. Beliaev Kemerovo Regional Clinical Hospital

location_facility: Bekes Megyei Kozponti Korhaz Dr. Rethy Pal Tagkorhaz

location_facility: University of Pennsylvania Cancer Center

type: Registry Identifier

title: Induction Study #2 - A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Oral Ozanimod as Induction Therapy for Moderately to Severely Active Crohn's Disease

summary: This is a study to explore the effect of oral ozanimod as an induction treatment for participants with moderately to severely active Crohn's Disease.


title: A Phase 3 Open Label, Randomized Study of BMS-986205 Combined With Nivolumab With or Without Chemotherapy Versus Chemotherapy in Participants With Previously Untreated Stage IV or Recurrent Non-Small Cell Lung Cancer

summary: This is a study of experimental medication BMS-986205 given with Nivolumab with or without chemotherapy compared to chemotherapy in participants with previously untreated stage IV or recurrent non-small cell lung cancer.

study_start_date_type: Anticipated

status: Withdrawn

location_country:
Italy
Austria
United States
Brazil
Switzerland
Mexico
Germany
France
Czechia
Greece
Japan
Australia
Spain
Turkey
Canada
Korea, Republic of
Taiwan